Published September 1, 2006 | Version v1
Journal article

Protective immunity provided by HLA-A2 epitopes for fusion and hemagglutinin proteins of measles virus

  • 1. Vaccine Branch, National Cancer Institute, National Institutes of Health, Bldg. 10-Rm 6B-09, NIH, Bethesda, MD 20892-1578 (United States) and Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205 (United States)
  • 2. Vaccine Branch, National Cancer Institute, National Institutes of Health, Bldg. 10-Rm 6B-09, NIH, Bethesda, MD 20892-1578 (United States)
  • 3. W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205 (United States)
  • 4. Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205 (United States)

Description

Natural infection and vaccination with a live-attenuated measles virus (MV) induce CD8+ T-cell-mediated immune responses that may play a central role in controlling MV infection. In this study, we show that newly identified human HLA-A2 epitopes from MV hemagglutinin (H) and fusion (F) proteins induced protective immunity in HLA-A2 transgenic mice challenged with recombinant vaccinia viruses expressing F or H protein. HLA-A2 epitopes were predicted and synthesized. Five and four peptides from H and F, respectively, bound to HLA-A2 molecules in a T2-binding assay, and four from H and two from F could induce peptide-specific CD8+ T cell responses in HLA-A2 transgenic mice. Further experiments proved that three peptides from H (H9-567, H10-250, and H10-516) and one from F protein (F9-57) were endogenously processed and presented on HLA-A2 molecules. All peptides tested in this study are common to 5 different strains of MV including Edmonston. In both A2Kb and HHD-2 mice, the identified peptide epitopes induced protective immunity against recombinant vaccinia viruses expressing H or F. Because F and H proteins induce neutralizing antibodies, they are major components of new vaccine strategies, and therefore data from this study will contribute to the development of new vaccines against MV infection

Additional details

Identifiers

DOI
10.1016/j.virol.2006.04.040;
PII
S0042-6822(06)00304-7;

Publishing Information

Journal Title
Virology
Journal Volume
352
Journal Issue
2
Journal Page Range
p. 390-399
ISSN
0042-6822
CODEN
VIRLAX

Optional Information

Copyright
Copyright (c) 2006 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved.